Abstract
Background
As important mediators of solute transport at the blood–brain and blood–cerebrospinal fluid barriers, ATP-binding cassette (ABC) transporters (including ABCB1, ABCC1, and ABCC2), impact the bioavailability of drugs and endogenous substrates in the brain. While several ABCB1, ABCC1, and ABCC2 single nucleotide polymorphisms (SNPs) have been identified, their impact on outcome after traumatic brain injury (TBI) is unknown.
Hypothesis
ABCB1, ABCC1, and ABCC2 SNPs are associated with Glasgow Outcome Scale (GOS) score after TBI.
Methods
DNA samples from 305 adult patients with severe TBI (Glasgow Coma Scale, GCS score ≤ 8) were genotyped for tagging SNPs of ABCB1 (rs1045642; rs1128503), ABCC1 (rs212093; rs35621; rs4148382), and ABCC2 (rs2273697). For each SNP, patients were dichotomized based on presence of variant allele for multivariate analysis to determine associations with GOS assigned at 6 months adjusting for GCS, Injury Severity score, age, and patient sex.
Results
For ABCB1 rs1045642, patients homozygous for the T allele were less likely to be assigned poor outcome versus those possessing the C allele [CT/CC; odds of unfavorable GOS = 0.71(0.55–0.92)]. For ABCC1 rs4148382, patients homozygous for the G allele were less likely to be assigned poor outcome versus those possessing the A allele [AG/AA; odds of unfavorable GOS = 0.73(0.55–0.98)].
Conclusions
In this single-center study, patients homozygous for the T allele of ABCB1 rs1045642 or the G allele of ABCC1 rs4148382 were found to have better outcome after severe TBI. Further study is necessary to replicate these very preliminary findings and to determine whether these associations are due to central nervous system bioavailability of ABC transporter drug substrates commonly used in the management of TBI, brain efflux of endogenous solutes, or both.
Similar content being viewed by others
References
Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta (GA): Center for Disease Control and Prevention, Nation Center for Injury Prevention and Control; 2010.
Dardiotis E, Fountas KN, Dardioti M, et al. Genetic association studies in patients with traumatic brain injury. Neurosurg Focus. 2010;28:E9.
Diaz-Arrastia R, Baxter VK. Genetic factors in outcome after traumatic brain injury: what the human genome project can teach us about brain trauma. J Head Trauma Rehabil. 2006;21:361–74.
Dardiotis E, Grigoriadis S, Hadjigeorgiou GM. Genetic factors influencing outcome from neurotrauma. Curr Opin Psychiatry. 2012;25:231–8.
Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–37.
Hartz AM, Bauer B. ABC transporters in the CNS—an inventory. Curr Pharm Biotechnol. 2011;12:656–73.
Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132:2517–30.
Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591–602.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–8.
Siedlinski M, Boezen HM, Boer JM, Smit HA, Postma DS. ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts. Pharmacogenet Genomics. 2009;19:675–84.
Ufer M, Mosyagin I, Muhle H, et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C > T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009;19:353–62.
Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442–8.
Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit. 2007;29:305–12.
Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood–brain barrier in patients with generalized epilepsy. Seizure. 2008;17:524–30.
Kim WJ, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010;20:249–56.
International HapMap Project. http://www.hapmap.org. Accessed Mar 2011.
Howie BN, Carlson CS, Rider MJ, Nickerson DA. Efficient selection of tagging single-nucleotide polymorphisms in multiple populations. Hum Genet. 2006;120:58–68.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480–4.
Marshall LF, Bowers-Marshall S, Klauber MR, et al. A new classification of head injury based on computerized tomography. J Neurosurg. 1991;75:S14–20.
Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol. 2001;54:979–85.
Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794:860–71.
Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–8.
Hung CC, Jen Tai J, Kao PJ, Lin MS, Liow HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics. 2007;8:1151–8.
Kwan P, Baum L, Wong V, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007;11:112–7.
Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9:487–8.
Dey S. Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opin Drug Deliv. 2006;3:23–35.
Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 + natural killer cells. Pharmacogenetics. 2001;11:293–8.
Owen A, Goldring C, Morgan P, Park BK, Chadwick D, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol. 2005;59:365–70.
Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia. 2009;50:898–903.
Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011;12:713–25.
Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol. 2011;201:261–83.
Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21:152–61.
van Assema DM, Lubberink M, Bauer M, et al. Blood–brain barrier P-glycoprotein function in Alzheimer’s disease. Brain. 2012;135:181–9.
Begley DJ. ABC transporters and the blood–brain barrier. Curr Pharm Des. 2004;10:1295–312.
Jedlitschky G, Grube M, Mosyagin I, et al. Targeting CNS transporters for treatment of neurodegenerative diseases. Curr Pharm Des. 2013. doi:10.2174/13816128113199990460.
Ito K, Olsen SL, Qiu W, et al. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J Biol Chem. 2001;276:15616–24.
Deeley RG, Cole SPC. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006;580:1103–11.
Budulac SE, Postma DS, Hiemstra PS, et al. Multidrug resistance-associated protein-1 (MRP1) genetic variants, MRP1 protein levels and severity of COPD. Respir Res. 2010;11:60.
Acknowledgments
The authors would like to thank Sandra Deslouches for expert technical assistance. This work is supported by University of Pittsburgh School of Medicine Clinical Scientist Training Program (JLC); NINDS R01 NS069247 (RSBC, PEE), P50 NS30318 (DOO, AMP, YPC, PMK, RSBC); NICHD T32 HD40686 (AAS); NCATS KL2 TR000146 (PEE); and NINR R01 NR008424 (YPC).
Disclosure
No financial disclosures.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Cousar, J.L., Conley, Y.P., Willyerd, F.A. et al. Influence of ATP-Binding Cassette Polymorphisms on Neurological Outcome After Traumatic Brain Injury. Neurocrit Care 19, 192–198 (2013). https://doi.org/10.1007/s12028-013-9881-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-013-9881-7